Showing results (21-30 of 114) with videos related to
Sort By:
Pageof 12
Cleveland Clinic Journal of Medicine|February 19, 2000
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromesM T Roe, S K Sapp, A M LincoffJAMA|March 10, 1999
Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for StentingS R Steinhubl, W A Tan, J M Foody, et al.Journal of the American College of Cardiology|December 1, 1994
Cell adhesion molecules in coronary artery diseaseY Jang, A M Lincoff, E F Plow, et al.The American Journal of Cardiology|May 4, 2000
The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trendsK R Campbell, E M Ohman, W Cantor, et al.American Heart Journal|October 2, 2001
Uniform platelet activation exists before coronary stent implantation despite aspirin therapyV L Serebruany, C C Cummings, A I Malinin, et al.American Heart Journal|October 20, 1998
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findingsN S Kleiman, A M Lincoff, E M Ohman, et al.European Heart Journal|November 1, 1995
An overview of the results of the EPIC trialR M Califf, A M Lincoff, J E Tcheng, et al.Physics in Medicine and Biology|June 1, 1982
Role of longitudinal diffusion in the extravascular pulmonary space on parameter estimates derived from data of multiple indicator dilutionH S Borovetz, W H Inskeep, A M Lincoff, et al.Clinical Cardiology|May 1, 1996
Restenosis--an open fileM Gottsauner-Wolf, D J Moliterno, A M Lincoff, et al.Heart (British Cardiac Society)|January 3, 2006
Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable riskD P Chew, D L Bhatt, A M Lincoff, et al.Pageof 12